<DOC>
	<DOCNO>NCT01590719</DOCNO>
	<brief_summary>This randomize , multicenter , double-blind , placebo-controlled study evaluate efficacy safety onartuzumab ( MetMAb ) combination mFOLFOX6 patient metastatic HER2-negative adenocarcinoma stomach gastroesophageal junction . Patients randomize 1:1 ratio receive either onartuzumab ( MetMAb ) placebo combination mFOLFOX6 . Patients may continue receive onartuzumab ( MetMAb ) placebo disease progression , unacceptable toxicity , patient physician decision discontinue treatment .</brief_summary>
	<brief_title>A Study Onartuzumab ( MetMAb ) Combination With mFOLFOX6 Patients With Metastatic Human Epidermal Growth Factor Receptor 2 ( HER2 ) Negative Gastroesophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Adult patient , 18 year age old Adenocarcinoma stomach gastroesophageal junction inoperable , metastatic disease , amenable curative therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy &gt; 3 month Presence tissue sample immunohistochemistry assay Met receptor HER2 status ( unknown ) Radiographic evidence disease ; measurable disease nonmeasurable evaluable disease , accord Response Evaluation Criteria Solid Tumors ( RECIST v1.1 ) ; Patients peritoneal disease would generally regard evaluable disease allow enter trial . For woman postmenopausal surgically sterile ; agreement use adequate method contraception ( e.g. , hormonal implant ) treatment period least 90 day last dose onartuzumab/placebo 6 month last dose oxaliplatin For men : agreement use barrier method contraception treatment period 90 day last dose onartuzumab/placebo 6 month last dose oxaliplatin Adequate laboratory value HER2positive tumor ( primary tumor metastasis ) Previous chemotherapy locally advance metastatic gastric carcinoma ( adjuvant neoadjuvant chemotherapy must complete least 6 month prior randomization ) Prior treatment investigational drug target hepatocyte growth factor ( HGF ) Met pathway History malignancy within previous 5 year , except appropriately treat presume cured carcinoma situ cervix , nonmelanoma skin carcinoma , Stage 1 uterine cancer , localize prostate cancer Receipt investigational drug within 28 day prior study start Clinically significant gastrointestinal abnormality , except gastric cancer ( e.g. , Crohn 's disease ) Significant history cardiac disease Significant vascular disease Infection human immunodeficiency virus , hepatitis B , hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>